by Deborah Erickson
It's the time of life every biotech CEO dreams of: a lead drug has won FDA approval; the company's stock price and its valuation have soared; clinicians clamor for the...
Idec and Coulter Face Off
Two makers of new antibody therapies for cancer are engaged in a fierce battle that's all about positioning. Idec recently won FDA's approval for {Rituxan}, which Genentech is co-promoting in the US. But young Coulter is proclaiming its {Bexxar}, still two years from market, will surpass {Rituxan} to become the gold standard treatment for non-Hodgkin's lymphoma. Will the companies limit each other's opportunities?
More from Business Strategy
More from In Vivo
• By
Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.
• By
From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.
• By
Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.